Axitinib
CAS 319460-85-0 5 FDA-DMF suppliersSmall Molecule
Overview
Axitinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors, used primarily in the treatment of renal cell carcinoma. Its ability to inhibit angiogenesis makes it an effective therapy for certain types of cancer.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Axitinib expires 11 Jul 2037. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.